Evidence map›Paper›PMID 35465297›Full record

ArticleTherapeutic advances in medical oncology2022

GUIDE: a randomised non-comparative phase II trial of biomarker-driven intermittent docetaxel

Ciara Conduit, Blossom Mak, Wenjia Qu, Juliana Di Lulio, Ronan Burder, Matthias Bressel, Thomas Cusick, Haryana M Dhillon, Richard De Abreu Lourenço, Craig Underhill and 9 more

Erratum issued Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Therapeutic advances in medical oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT04918810 (A Phase II Trial of Biomarker-driven Intermittent Docetaxel in Metastatic Castration-resistant Prostate Cancer), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04918810 phase2terminatednot on this map

A Phase II Trial of Biomarker-driven Intermittent Docetaxel in Metastatic Castration-resistant Prostate Cancer (mCRPC)

TypeinterventionalSponsorAustralian and New Zealand Urogenital and Prostate Cancer Trials GroupRan2022 to 2024Enrolled6ConditionsCastration Resistant Prostatic CancerArmsDocetaxel intermittent
3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

19 authors at 9 institutions in 1 country.

Ciara ConduitAustralian and New Zealand Urogenital and Prostate (ANZUP) Cancer Trials Group, Camperdown, NSW, Australia Personalised Oncology, Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia.
Blossom MakChris O'Brien Lifehouse, Camperdown, NSW, Australia Garvan Institute of Medical Research, Darlinghurst, NSW, Australia The University of Sydney, Sydney, NSW, Australia.ORCID https://orcid.org/0000-0003-3068-2498
Wenjia QuGarvan Institute of Medical Research, Darlinghurst, NSW, Australia.
Juliana Di LulioCentre for Biostatistics and Clinical Trials (BaCT), Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
Ronan BurderCentre for Biostatistics and Clinical Trials (BaCT), Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
Matthias BresselCentre for Biostatistics and Clinical Trials (BaCT), Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
Thomas CusickAustralian and New Zealand Urogenital and Prostate (ANZUP) Cancer Trials Group, Camperdown, NSW, Australia.
Haryana M DhillonAustralian and New Zealand Urogenital and Prostate (ANZUP) Cancer Trials Group, Camperdown, NSW, Australia Centre for Medical Psychology and Evidence-Based Decision-Making, School of Psychology, Faculty of Science, The University of Sydney, Sydney, NSW, Australia Psycho-Oncology Cooperative Research Group, School of Psychology, Faculty of Science, The University of Sydney, Sydney, NSW, Australia.
Richard De Abreu LourençoCentre for Health Economics Research and Evaluation, University of Technology Sydney, Sydney, NSW, Australia.
Craig UnderhillBorder Medical Oncology Research Unit, Albury Wodonga Regional Cancer Centre, Albury, NSW, Australia University of NSW Rural Clinical School, Albury, NSW, Australia.
Javier TorresGoulburn Valley Health, Shepparton, VIC, Australia Rural Medical School, The University of Melbourne, Shepparton, VIC, Australia.
Megan CrumbakerGarvan Institute of Medical Research, Darlinghurst, NSW, Australia St. Vincent's Clinical School, University of New South Wales, Sydney, NSW, Australia The Kinghorn Cancer Centre, St. Vincent's Hospital Sydney, Darlinghurst, NSW, Australia.
Florian HoneyballDubbo Base Hospital, Dubbo, NSW, Australia School of Rural Health, The University of Sydney, Dubbo, NSW, Australia.
Anthony LintonThe University of Sydney, Sydney, NSW, Australia Concord Cancer Centre, Concord Repatriation General Hospital, Concord, NSW, Australia.
Ray AllenAustralian and New Zealand Urogenital and Prostate (ANZUP) Cancer Trials Group, Camperdown, NSW, Australia.
Ian D DavisAustralian and New Zealand Urogenital and Prostate (ANZUP) Cancer Trials Group, Camperdown, NSW, Australia Eastern Health Clinical School, Monash University, Box Hill, VIC, Australia Eastern Health, Box Hill, VIC, Australia.ORCID https://orcid.org/0000-0002-9066-8244
Susan J ClarkGarvan Institute of Medical Research, Darlinghurst, NSW, Australia UNSW Sydney, Sydney, NSW, Australia.
Lisa G HorvathChris O'Brien Lifehouse, Camperdown, NSW, Australia Garvan Institute of Medical Research, Darlinghurst, Sydney, NSW, Australia The University of Sydney, Sydney, NSW, Australia Royal Prince Alfred Hospital, Camperdown, NSW, Australia.
Kate L MahonChris O'Brien Lifehouse, 119-143 Missenden Rd, Camperdown, NSW 2050, Australia.ORCID https://orcid.org/0000-0002-6801-0841
The University of Sydney · AUGarvan Institute of Medical Research · AUPeter MacCallum Cancer Centre · AUAustralian and New Zealand Urogenital and Prostate Cancer Trials Group · AUAlbury Wodonga Health · AUEastern Health · AUGoulburn Valley Health · AUUniversity of Technology Sydney · AUWalter and Eliza Hall Institute of Medical Research · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: To determine the efficacy and safety of intermittent docetaxel chemotherapy guided by circulating methylated glutathione S-transferase Pi-1 ( Patients and Methods: GUIDE (NCT04918810) is a randomised, two-arm, non-comparative phase-2 trial recruiting 120 patients at six Australian centres. Patients with Prostate Cancer Working Group-3 defined metastatic CRPC who are commencing docetaxel 75 mg/m Results and Conclusion: The results of this trial will generate data on the clinical utility of

Indexed as

biomarkersglutathione s-transferase Pipatient-reported outcome measuresprostate neoplasmsprostate-specific antigenquality of life

Identifiers

PMID35465297
PMCPMC9019311
OpenAlexW4226165260

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.